Review Article

Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics

Introduction

The research and development of nanoscale systems are gaining popularity from the last few years due to their associated potential applications in the pharmaceutical and biotechnological field. Nanoparticles (NPs) are small colloidal particles made of biodegradable or non-biodegradable materials. The average diameter of NPs ranges from 10 to 1000 nm, but the particles of diameter <200 nm are often referred as nanomedicine. ¹ The drug is dissolved, dispersed, encapsulated, entrapped or attached to NP matrix. ^2,3 Depending on the method of preparation, nanospheres (the drug is uniformly dispersed in a matrix) or nanocapsules (the drug is confined in a cavity) are obtained which possess different properties and release characteristics suitable for best drug delivery or drug encapsulation. ⁴

Due to the small size of NPs they can penetrate tissues and small capillaries offering advantages including long circulation time, improvements in the target to non-target concentration ratio, increased residence at target site and improved cellular uptake. ⁵ This is achieved by opsonization of NPs followed by macrophage activation in circulation. The surface area per unit mass of NPs compared with other multi-particulate systems is the unique characteristic feature which adds up to their functionality. This may be useful in improving the aqueous solubility of a drug candidate, which is an important physicochemical factor further affecting its dissolution and bioavailability. ⁶

Various types of nanoparticulate systems were developed for drug delivery, including polymeric NPs ^7,8 lipid NPs (viz. first generation-solid lipid NPs and second generation-nanostructured lipid carriers), ⁹ polymeric micelles, liposome, nanotubes, nanocrystals, dendrimer, metallic NPs, ¹⁰ quantum dots and magnetic NPs. ¹¹

NPs are employed for diverse applications, including site-specific and targeted drug delivery in cancer, ¹² as the leaky and defective architecture of tumour allows interstitial access to NPs which is popularly known as enhanced permeation and retention. ^13,14 These are explored for drug delivery through different routes of administration including oral, ¹⁵ pulmonary, ¹⁶ nasal, parenteral, ¹⁷ ocular, ¹⁸ brain ¹⁹ and dermal-transdermal routes. ^20,21

The reports focused on cyclodextrin (CD) which discusses its role in oral cancer therapy, ²² pharmaceutical and biomedical applications of CD-based nanogels ²³ and in drug and gene delivery are available. ^24-27 Despite the varied potential of NPs, they possess lacuna related to some physicochemical and pharmaceutical aspects. These challenges could include lower drug loading and entrapment efficiency, etc. The problems related to NP drug delivery which can be resolved with the aid of CDs are addressed in this review including poor drug loading into NPs, physical and chemical stability, specificity of drug target, pharmacokinetics and bioavailability related issues and modified drug release along with discussions on safety and efficacy aspects of CD in drug delivery. Especially this review is focused on the application of CDs in the elimination of difficulties in nanoparticulate formulation and improvement of their pharmaceutical and therapeutic performance. Additionally this manuscript provides insights into the theranostic applications of CDs.

Cyclodextrin: overview

CDs are amphiphilic cyclic oligosaccharides containing at least six D-(+) glucopyranose units attached by α-(1, 4) glycosidic bonds. ²⁸ These are also known as cyclomaltodextrins or cycloamyloses. CDs are obtained from enzymatic degradation of starch from potato, corn and other sources. This was discovered by French scientist Villiers who isolated crystalline compound called ‘cellulosine’ in 1891. ²⁹ In following decade later, the role of glycosyltransferase from Bacillus macerans in production of CDs from starchwas demonstrated by Austrian microbiologist Schardinger. He identified naturally occurring CDs-alpha, beta and gamma which are referred to as Schardinger sugars. Moreover, he also identified β-CD as ‘cellulosine’ depicted by Villiers. ³⁰ Nowadays CDs are exploited for various applications in food, biotech, pharma, cosmetic and textile industry. ^31-33

Natural CDs α, β and γ-CDs with respectively 6, 7 and 8 glucopyranose units were included in the generally regarded as safe (GRAS) list of the USFDA for use as a food additive in 2004, 2001 and 2000 respectively. The recent regulatory status of natural CDs is revealed in Table 1. Two important CD derivatives hydroxypropyl-β-CD (HP-β-CD) and sulfobutylether-β-CD (SBE-β-CD) were cited in the FDA’s list of ‘Inactive Pharmaceutical Ingredients’ used in novel pharmaceutical applications along with natural CDs. ³⁴ The rational modifications of CD can be carried out for improving interaction with the biological membrane by increasing their lipophilicity, improving interaction of hydrophobic drugs with CD and allowing self-assembly of CD.

CDs are commonly used for aqueous solubility enhancement of drug for oral delivery as well as in parenteral delivery as a result of their ability to form an inclusion complex with chemical moiety. ^35,36 They form complexes with a variety of molecules including organic, inorganic and organo-metallic compounds by so called molecular recognition phenomenon while their ability to form complexes with enantiomeric species is known as chiral recognition. ³⁷ The advantages and disadvantages of the CDs are listed in .CDs are employed in the drug delivery due to their versatile potential related to drug permeability enhancement, bioavailability enhancement, improvement of safety and efficacy, improvement in drug and formulation stability, modified drug release and enhancement of drug loading, protein and peptide delivery, colon specific delivery, transdermal delivery, nasal delivery, pulmonary delivery ^38-40 and gene delivery. ⁴¹

Close

Figure 1. Advantages and disadvantages of cyclodextrins in nanoparticulate formulations.

Cyclodextrin-based nanoparticles

The CDs are widely studied and employed in solubility enhancement of poorly soluble drugs. CD can play a vital role in improving the performance of NP formulation. The natural CDs and their derivatives such as HP-β-CD and HP-γ-CD complexes or self-assemble in nanoscale aggregates in aqueous solutions. ⁴² They can be exploited for improving drug loading, formulation stability, enhancing or improving absorption and bioavailability along with retained/improved safety and efficacy and modifying drug release through nanosystems.

The factors which affect in vitro characteristics of CD NPs including particle size, drug loading and release from formulation ^43-45 and stability ⁴⁶ are enlisted in Table 2.

Factors affecting in vitro properties of CD nanoparticles

Nature, type and length of CD substitution

The natural CDs are modified by substituting them with different functional moieties with varied nature and length which provide cationic, anionic or nonionic amphiphilic nature to the CD. These modifications are necessary for improving the interaction of CDs with hydrophobic drugs which ultimately affects drug loading and drug release from NP formulation. The partially acylated β-CD regulate mean particle size of NPs and therefore the stability of the system. ⁴⁷ The alteration in drug loading, particulate size, entrapment efficiency and stability of formulation with modification on the primary and secondary face of β-CD are demonstrated in the literature. ^48,49 The correlation between the structure of the amphiphilic-CDs and their ability to form nanospheres shows that for the compounds that have hydrophilic lipophilic balance values are greater than 8.0 are water soluble, able to self organize in water to form nanospheres. Whereas, for the compounds with hydrophilic lipophilic balance values lower than 7.4 are soluble in organic solvent rendering the preparation of NPs by nanoprecipitation technique possible.

Physicochemical characteristics of the drug

The most of drugs are either weak acids or weak bases. They vary in their physicochemical properties. The association constant of drug: CD, octanol: water partition coefficient, molecular weight, solubility, size and shape of drug (guest molecule) are considered to be influential factors for drug loading, entrapment efficiency and drug release from CD based NP. ^50,51 It is reported that in the study by Memisoglu-Bilensoy et al where hydrocortisone, testosterone and progesterone were drugs candidates for loading in CD based nanocapsule or nanosphere. Regardless of the technique of drug loading the progesterone a lipophilic drug with higher association constant and partition coefficient has reported having higher drug loading than other drugs. ⁵²

Drug-CD complex properties

The complexation and electrostatic interaction between drug and CD can alter the pharmacokinetic profile of drug significantly. The effect of the presence of CD on Cmax, volume of distribution, mean residence time and renal clearance of drug was demonstrated by Charman et al. ⁵³ Drug-CD complex can be considered as molecular encapsulation. The CD molecule shields drug at least partly from an attack of the immediate external environment or reactive molecules. In this way, it may reduce or prevent drug degradation. The CD mimics enzyme catalysis or inhibition. The degree of stabilization/destabilization drug after the formation of inclusion complex depends mainly on the fraction of drug inside complex and rate of drug degradation inside complex. ⁵⁴

Preparation and loading technique

The method and sequence of addition of the drug, CD and solvents varies with alteration in the preparation technique of CD-based NP. The assessment between the conventional method and emulsification method demonstrated that these methods leads to development to different colloidal structures, with different size and size distribution as well as different colloidal stabilities to nanocarrier. The residual amount of organic solvent may avoid coalescence of the colloidal system but their physiological effects should not overweigh the stability. ⁵⁵ High drug loading technique in which preformed steroidal drug: CD complexes were utilized along with the addition of drug during preparation have shown more drug loading in nanospheres than the conventional drug loading technique. The drug loading efficiency for nanocapsules is independent of techniques used for loading for steroidal drugs. ⁵²

Methods of preparation for cyclodextrin based nanoparticles

Preparation technique dictates the formation of either nanospheres or nanocapsules. The drug loading can be carried out directly during preparation (conventional loading) or using previously formed drug: CD complexes (preloading) or a combination of both (High loading). The schematics of CD-NP preparation is depicted in the graphical abstract. Various methods of preparation of such CD based nano-systems are cited below.

Polymer precipitation methods

In these techniques, polymer is precipitated with formation of either nanospheres or nanocapsules. These are easy and speedy production techniques with comparatively uniform size distribution. The mild solvents like ethanol, butanol or acetone may be selected for these techniques to avoid toxic residues generated from solvents like methylene chloride and chloroform, etc. Nonsurfactant NPs can be prepared in presence of CDs which can avoid complications associated with surfactants. Based on sequence and method of addition of drug and polymer, these preparation techniques can be divided as follows:

Solvent injection method

Hydrophobic components are dissolved in water-miscible organic solvent while hydrophilic components are dissolved in the aqueous phase. Organic phase injected into the aqueous phase, diffusion of organic phase into later phase leads to NPs formation.56 This method has an advantage that the based on the nature of drug and its solubility, it can be dissolved in either aqueous phase or organic phase.

Solvent evaporation method

In this method, a CD is dispersed in an organic solvent. Drug solution in the same solvent added to a CD dispersion. Then aqueous phase is added to this mixture and an organic solvent is evaporated to obtain nanospheres or nanocapsules which will be further freeze dried. ⁵⁷

Solvent diffusion

The solution of a drug in ethanol is slowly added to aqueous phase with a peristaltic pump with continuous stirring to form nanocrystals. The nanocrystal dispersion is clarified by centrifugation in the refrigerated condition which is then freeze dried. ⁵⁸

Inotropic gelation method

Sodium carboxy methyl β-CD (SCM- β-CD) or its mixture with pentasodium tripolyphosphate (TPP) in aqueous form was added to chitosan (CS) solution under magnetic stirring. The positively charged CS and negatively charged SCM- β-CD and/or TPP spontaneously react via inotropic gelation to form NPs. ⁵⁹

Utility of Cyclodextrin functionalized nanoparticles

Nanoparticulate systems were employed for delivery of drugs as well as biomolecules. The obstacles in NP drug delivery can be overcome with the CD. The major avenues in the formulation of NP systems where CDs can be utilized to cause intervention for flawless drug delivery are depicted in .

Close

Figure 2. Applications of cyclodextrin based nanoparticles.

Improvement of drug loading and entrapment efficiency

The higher drug loading is usually necessary in particulate systems for efficient utilization of the formulation system or carrier. The free energy of the host-guest complex is directly associated with binding constant and thus drug entrapment efficiency. The physicochemical properties of drug viz. molecular mass, aqueous solubility, partition coefficient and K_1:1 association constant and loading technique mainly affect drug loading in CD functionalized NPs. ⁵¹

Drug loading can be improved by substituted semi-synthetic CDs. Free paclitaxel in poly (anhydride) NPs has reported to show poor drug loading in comparison with its complex with HP-β-CD. The drug loading of paclitaxel was improved 500 folds with HP-β-CD against its polymeric NP. ⁶⁰ In an investigation by Yuan et al it was revealed that chitosan-graft-β–CD (CD-β–CS) has improved drug encapsulation of Ketoprofen by 1.36 against CS NPs. The order of entrapment efficiency was CS < CD9.6-β–CS < CD14-β–CS < CD20-β–CS, indicating significant improvement in entrapment with an increasing degree of substitution of CD on CS. This might be because that -CD could effectively load poorly water-soluble drugs into the cavity, additionally, this an increasing substitution shows increasing zeta potential. ⁶¹ Drug loading of azole antifungal drugs was also improved when β-CD was modified on its primary and secondary face with substituent’s of varying chain length and bond type. It has been claimed that β-CD modified on the primary face with 6-carbon aliphatic chain with amide bond shows more drug loading than that of modification on the secondary face with ester bonds and 6-Carbon aliphatic chains. ⁶² Encapsulation 6-coumarin in CS NPs was improved with various CDs. ⁶³ It is revealed that Erlotinib complex with β-CD sulfobutyl ethers (Captisol®) improve drug loading and entrapment efficiency in PLGA NPs along with improvement in solubility and cellular uptake in non small cell lung carcinoma. ⁶⁴

The ability of CDs increase drug loading and entrapment efficiency can be assigned to their ability to accommodate hydrophobic moieties.

Stability enhancement

The stability of the nanoparticulate colloidal drug delivery system is a matter of concern to formulation scientists. The developed micro-particulate formulations shall be stable during shelf life. Zeta potential and stability of the nanoparticulate formulation is affected by type of excipients (usually by nature of polymers or lipid) and characteristics of alkyl chain in CD molecule. ⁴⁶

As discussed earlier nature and type of CD entail the characteristics of NPs, it was demonstrated that sulfated β-CD get associated with acylated CD to improve stability of nanospheres.65 In a recent study by Chen et al reports a kind of supramolecular assemblies constructed from two water-soluble and biocompatible saccharides, sulfonato-β-CD and CS shows adequate stability at temperature 10 to 70°C. ⁶⁶ β-CD has been utilized as capping agent and stabilizing agents for synthesis of copper NPs where it protects against oxidation of NPs and improves antibacterial activity. ⁶⁷ A report demonstrating improved stability of paclitaxel loaded solid lipid NPs has shown that HP-β-CD is more effective over hydroxy β-CD to control the particle size, polydispersity index and stability of NPs. ⁶⁸ The possible reason for stability of colloidal NPs using CDs may be balance created by hydrophilic and hydrophobic functions or it can be attributed to the steric interactions between alkyl chains in CD.

Improvement in solubility, dissolution or bioavailability profile of drug

The hydrophilic affection of a drug is vital for drug loading in NPs and drug release from delivery system which consequently may affect the pharmacokinetics of the drug. Several approaches have been reported in literature for solubility enhancement of poorly soluble drugs. CD functionalized NPs are also widely employed for this purpose owing to the benefits offered by the CD discussed earlier.

It was reported that the bioavailability of raloxifene a selective estrogen receptor modulator, increased almost 2.6 folds by formation of CD/CS NPs using SBE-β-CD along with increasing drug solubility. ⁶⁹ It is revealed that CPT loading in CD NPs was higher as compared to polymeric NPs, with its solubilization and stabilization. ⁷⁰ A research report claims that there is increase in dissolution and bioavailability almost twice that of plain erlotinib (anticancer drug) when it is delivered in the form of erlotinib CD nanosponge complex. The improvement in solubility and dissolution of erlotinib was attributed to loss in crystallinity, particle reduction up to the molecular level and hydrogen bonding between the drug and CD-nanosponge. ⁷¹ An interesting case reported regarding drug dutasteride which is insoluble in water (less than 0.038 ng/mL), shows 90% dissolution of the dutasteride from all the HP-β-CD nanostructures in dissolution media within nine minutes. ⁷² In an investigation by Huarte et al where HP-β-CD, M-β-CD and SP-β-CD, at a concentration of 20% w/v, were capable to improve the aqueous solubility of CPT by factors of 24, 67 and 22, folds respectively. This indicates the significance of nature of CD having methyl groups in M-β-CD which enlarge the whole cavity of the molecule by extending the secondary hydroxyl side and narrowing the primary hydroxyl side of the cone and improves solubility to larger extent. ⁷³ The report indicating β-CD-curcumin NP complex has improved dissolution rate of curcumin by ten folds and improved permeability enhancement across skin. ⁷⁴

Insulin is a polypeptide hormone to control blood sugar level. The oral delivery of insulin has limitations due to its instability in under gastric environment. Carboxymethyl-β-CD-grafted CS (CMCD-g-CS) allows pH-triggered oral delivery of insulin at pH 7.4. The oral bioavailability insulin with this pH triggered grafted NPs as claimed by Song et al is far better than the bioavailability of plain insulin by subcutaneous or oral insulin. ⁷⁵ Alginate/trimethyl-CS NPs were reported for oral delivery of insulin containing cationic-β-CD, this also shows pH- trigger for simulated intestinal fluid (pH 6.8). It has shown to improve the permeability of insulin across Caco-2 cell layer. ⁷⁶ HP-β-CD complexed insulin was encapsulated in polymethacrylate based copolymer NPs. Insulin has shown to retain its activity with expected enhanced oral absorption. ⁷⁷ CMCD-g-CS has been additionally explored by Song et. al for oral delivery of other protein-bovine serum albumin showing its potential for delivery of proteinaceous candidates by oral route. ⁷⁸ CD-based star synthetic polymers having hydrophobic arms of acrylate group improved the cellular uptake of NPs. These acrylate groups can protonate at pH 6 which escapes the NPs from endocytotic vesicles and intracellular drug release acting as a platform for nanochemotherapeutics. ⁷⁹ A detailed account of effect of CDs on drug delivery through the biological membrane was reviewed by Loftsson et al. ⁸⁰ Docetaxel /SBE-β-CD/CS NPs showed capability in improving the small intestinal absorption and bioavailability by inhibiting the efflux of drug. ⁸¹

Site specific/targeted drug delivery

Delivery of optimal drug quantity safely to a specific site for effective therapeutics stems from the idea of minimizing risk to benefit ratio of the drug. ⁸² CD-NPs have a potential of reducing drug toxicity with site specific/targeted delivery.

CD was utilized for siRNA delivery to target tumour cells the NP system consisting of CD, transferrin (targeting ligand) and polyethylene glycol. ⁸³ CDs utilized in development of NP for siRNA delivery works as polycation allow assembling with different size and types of nucleic acids through the electrostatic interactions. The formed nano-assemblies are resistant to the nuclease degradation. A reduction in both specific messenger RNA and protein RRM2 (M2 subunit of ribonucleotide reductase) was reported in phase I clinical trial with this NP system for the targeted treatment of solid tumours. ⁸⁴ The α–β CD dimer synthesized via click chemistry was utilized as a linker to connect hydrophobic and hydrophilic segment to form self assembled noncovalently connected micellar nanoassembly. Its application in ‘tumour triggered targeting’ was revealed through endocytosis experiments to confirm selective uptake of drug loaded micellar nanoassembly. ⁸⁵ The schematic of intracellular delivery biomolecule/drug using CD as a carrier is depicted in .

Close

Figure 3. Schematic of CD as a carrier for intracellular drug delivery.

Site specific delivery of indomethacin in polyethylamine-CD nanoassemblies to intestinal tissues resulted in lower gastric irritation with sustained drug release and mucoadhesive capabilities were reported. ⁸⁶ An interesting case of dual stimuli-responsive supramolecular polymeric NPs based on poly(α-CD) and acetal-modified β-CD-azobenzene reported by Dai et al. According the claims in this investigation, the drug release of methotrexate in faster in acidic conditions (pH 5.0), while ultraviolet (UV) irradiation shows burst release which slow down after the withdrawal of UV light indicating the promising application of CD based NPs in drug delivery to cancerous cells having acidic environment. ⁸⁷ Gene silencing with siRNA conjugated with β-CD was demonstrated by Malhotra et al. It is shown that modified β-CD has the ability of delivering RNA to cancer cells by simple complexation with polycationic lipids (lipoparticle) and by formulating inclusion complexes adamantyl-PEG-dianisamide with the CD-RNA conjugate NPs. ⁸⁸ The uptake mechanism of CD based NPs by tumour associated macrophage was demonstrated with murine glioma model which can used potentially to target malignant brain tumours. ⁸⁹ Lanthanide doped upconversion NPs absorbs near-infrared waves and convert them to UV light, additionally possess ability to penetrate deep tissues with the potential of bioimaging and treatment of diseases of deep tissues. Carboxymethyl-β-CD allows hydrophobic upconversion NPs to stay solution improving its functionality in cancer detection and treatment. ⁹⁰ It has been demonstrated in mice, significant proportion of melarsoprol from HP β-CD complex distributed into brain which could a positive avenue for its cerebral delivery in trypanosomiasis. ⁹¹ Biotin modified β-CD gold NPs of paclitaxel were reported for pH- responsive targeted anticancer activity and lower toxicity to normal cells due to enhanced water solubility. ⁹²

Curcumin loaded-HP-γ-CD water soluble complex encapsulated in CS NPs not only enhance the passive targeting but also lead to high drug release within the cancer cells and enhance its efficacy. ⁹³ CDs modified with folic acid for targeted was disclosed by Hattori. ⁹⁴ Targeting efficiency of CDs modified with folic acid was exemplified with anticancer drug doxorubicin using folate receptor protein and Caco-2 cell layer model. Applications of CDs in targeting NPs were reviewed by Erdoar et al. ⁹⁵

Mucoadhesion/bioadhesion characteristics

Bioadhesive formulations are proposed to increase contact time with mucosa and in turn, improve drug absorption. CD-nanosystems possess potential of prolonging drug release through mucoadhesion/bioadhesion. The bioadhesive property of CD may facilitate to troubleshoot the drug permeability by increasing contact time of drug at surface of the mucosa. The chemical modification of CD can improve mucoadhesive/bioadhesive characteristics of NPs. ^96,97 The schematic of chemically modified CD carrier with bioadhesive or mucoadhesive abilities is illustrated in .

Close

Figure 4. Schematic of chemically modified CD molecule for bio-adhesive/ muco-adhesive application.

SBE-β-CD/CS NPs for ocular drug delivery with prolonging the residence time of naringenin, which is useful for the treatment of age-related macular degeneration. ⁹⁸ Bioadhesive CS-coated CD-based supramolecular nanomicelles which improves the oral bioavailability of doxorubicin along with this they claimed to have a biodegradable and biocompatible nature too. ⁹⁹ A study showing a comparison between poly (anhydride) NPs of HP-β-CD and NPs coated with poly(ethylene glycol) 6000 for oral antigen/drug delivery has shown to possess cytoadesive nature but later shows more bioadhesion. ¹⁰⁰ β-CD modified mesoporous silica NPs with hydroxyl, amino, and thiol groups were reported in the literature. A comparison of their mucoadhesive properties and potential as a drug delivery system for superficial bladder cancer therapy revealed that thiol-functionalized NPs exhibit significantly higher mucoadhesivity on the urothelium as compared to the hydroxyl- and amino-functionalized NPs. ¹⁰¹

Controlled and sustained drug delivery

Controlled and sustained drug delivery systems were developed for reducing the dosing frequency of drug. These systems provide a drug release over a predefined time period with the possibility of reducing the required dose and subsequently related side effects of the drug. Sustained or controlled release can be achieved with CD functionalized NPs. The drug Release rate and amount of drug released from CD functionalized NPs could be affected by preparation method, nature of CD, grafting or crosslinking agents, aqueous solubility of polymer and drug. ^102-104

The biocompatible supramolecular assembly employing sulfonato-β-CD polysaccharides and CS as building blocks and different physiological pH as controlling method explored by for controlled release of berberine. The sulfonato-β-CD based carrier loaded with natural molecule berberine, allows drug release at intestinal pH and shows stability in the gastric environment. The schematics of sulfonato-β-CD/CS based supramolecular assembly is shown in . ⁶⁶ An interesting case of cationic-β-CD/5-Flurouracil within alginate/CS nanoflowers has been presented by Lakkakula et al which provide sustained drug release in both acidic (pH 2.3) and basic (pH 7.4) conditions with significantly higher encapsulation efficiency and lower polydispersity index. ¹⁰⁵ Potent and long lasting (~22 hours) inhibitory activity on the pressor response of angiotensin-I was demonstrated through arterial blood pressure measurements in rats after administration of captopril-CD NPs. ¹⁰⁶ Docetaxel-loaded NPs assembled from β-CD/calixarene giant surfactants shows initial burst release followed by longer drug release for about 30 to 60 hours. ¹⁰⁷ Insert therapeutics-101, a linear CD-containing polymer conjugate of CPT formulated in NPs is under clinical trial showing prolonged release. ¹⁰⁸ Docetaxel loaded in heptakis (2-O-oligo (ethyleneoxide)-6-hexadecylthio-)-beta-CD has shown slow release allowing prolonged cell arrest in mitosis.109 It was demonstrated that copolymer containing β-CD can be utilized for self assembly hydrophobic drugs in nanovehicles to exhibit sustained release. Conjugates of poly (DL-lactide-co-glycolide) on amino CDs in NPs were reported for bovine serum albumin delivery showing triphasic release for 27 to 28 days.110 Injectable and biodegradable supramolecular hydrogel formed from two-level self-assembly of amphiphilic polymer methoxy poly(ethylene glycol)-b-poly (ε-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-un-decanone) (mPECT) and polypseudorotaxane formed by α-CD and PEG blocks demonstrated release of NPs of ≈50 nm from hydrogel lasting for more than 3 weeks and subcutaneous biodegradability for ≈2 weeks. ¹¹¹

Close

Figure 5. Schematic of chemically modified sufonato-CD (SCD) molecule for pH triggered drug delivery and controlled release of berberine. Reprinted (adapted) with permission from Chen et al. 66

Safety and efficacy aspects of cyclodextrin nanoparticles

The toxicity profiles of CDs depend on the route of administration. CDs are nontoxic by the oral route of administration. CDs forms complex with biliary salts and cholesterol in the gastrointestinal tract in a reversible manner. CDs administered by the intravenous route are hemolytic in action. ³⁷ However, some derivatives of CD like HP-β-CD is well tolerated and noncarcinogenic in some animal studies and some reports that it is unsuitable for use as a vehicle in oral (gavage) pre-clinical toxicology studies in the RccHan:WIST rat, owing to the effects on liver enzymes, urinary volume and microscopic findings in the kidneys. ^112,113 So, the use of HP-β-CD should be cautioned. However, the oral administration of β-CD nanosponges has indicated it’s the safety in animal studies allowing one to use the β-CD in drug delivery. ¹¹⁴

The ability of CD to overcome a barrier in the formulation of poorly water-soluble drug CPT with improving its pharmacokinetics, pharmacodynamics and efficacy was demonstrated by CRLX101 formulation. It is composed of β-CD-poly (ethylene glycol) copolymer conjugated to CPT which appeared to be safe and effective in phase 1/2 clinical studies. ¹¹⁵ Sugammadex is a selective relaxant binding agent with a modified γ-CD, and it is specifically designed to grab and encapsulate the aminosteroidal neuromuscular blocking agents such as rocuronium or vecuronium. Various clinical reports suggested the safety and efficacy of Sugammadex. ¹¹⁶ Hydroxypropyl- and sulphobutyl ether CDs are recognized as safe and used in parenteral solutions. Although these more water-soluble derivatives of CD are well-tolerated α-CD, β-CD and methyl-CDs are considered toxic by parenteral route. ¹¹⁷ The anticancer activity and acute toxicity of docetaxel-HP-β-CD is comparable to Taxotere, but CD based formulation not lead to hypersensitivity, which was observed in Taxotere treated group. ¹¹⁸ It was demonstrated that α-methyl prednisolone conjugated CD polymer NPs significantly decrease arthritis score in animals which could be a safer and effective approach for rheumatoid arthritis treatment. ¹¹⁹ Lower hemolytic activity and significantly low minimum inhibitory values were observed for azole antifungals in amphiphilic CD compared to their ethanolic solution indicating increased efficacy by nanospheres of CD drug inclusion complexes. ⁶² Moreover, uses of modified CDs reduce/eliminate the need of surfactant in NP preparation further improving their intravenous safety. ¹²⁰ The promising improvements in antiviral activity of acyclovir by incorporating it with β-CD-poly(4-acryloyl morpholine) monoconjugate has been reported along with biocompatibility assays to prove safety. ¹²¹ Nanosponges prepared by crosslinking of beta CDs with diphenyl carbonate were reported in recent studies encapsulating dexamethasone for ocular delivery which with demonstrated improved permeability and safety. ¹²²

These reports indicating safety and improved efficacy of CD could open new avenues in nanoparticulate drug delivery. One can precisely design and synthesize CD derivatives based on these previous studies. The recent regulatory status of CDs as discussed earlier can serve as evidence for its potential to be utilized it in drug and gene delivery. The safety evaluation and careful selection of CD derivatives to improve pharmaceutical characteristics can provide a unique opportunity in drug delivery.

An account of recent advances in CDs for optimal drug delivery

CDs offer various benefits as discussed earlier in addition to this it possesses the ability to tailor-made the drug release to the target site. They possess the inherent ability to accommodate or associate with the wide variety of small molecules, proteins, peptide and aptamers. This can be achieved by careful selection of the proper type of CD or through the chemical modifications of CDs for the predetermined purpose of the delivery. The chemical modifications of CD are carried out for increasing interaction of CDs with biological membrane, enhancement of solubility and dissolution of the drug, accommodating hydrophobic and hydrophilic drugs, controlled or sustained release of the drug release, stimuli responsive drug release or for improving the stability of the formulation. ¹²³ Some recent case studies of the CDs in the optimal drug delivery of drugs, proteins, peptides and aptamers are reported in the Table 3. ^124-140 CDs can be moulded into various types of formulation for proving ease the drug delivery by diverse routes of administration.

Interested authors can read the recent review by Shelley and Babu on how CDs can be employed beneficially to boost the characteristics of the polymeric, magnetic, lipid, metallic and mesoporous NPs. ¹⁴¹ A story of CDs for biomedical applications especially providing the details of supramolecular interactions by Mejia-Ariza et al is interesting to read. ¹⁴² Add on to the accounts of CDs are provided by the reviews published in recent years giving up to date version of available opportunities for the researchers working on their use in the development of nanovesicles for diverse relevance in pharmaceutical and biomedical field. ^143-145

Theranostic applications of cyclodextrins

Theranostics is an emerging therapeutic prototype that enables synchronized execution and accomplishment of diagnosis and therapeutics for the betterment of treatment. Therapeutic and diagnostic job in one delivery formulation tender combined approach, theranostic agents facilitate disease diagnosis, therapy, and instantaneous monitoring of advancement treatment and efficacy, all with one pharmaceutical agent. ¹⁴⁶ Theranostics is extensively explored in the diagnosis and treatment cancer due to unique rewards offered by stimuli-responsive nanosoldiers in malignant pathology, allowing the nanocarrier to respond specifically to the pathological ‘triggers’ such as pH, enzyme, redox microenvironment, temperature and small molecules for smart delivery of molecules to tumour. ¹⁴⁷

CD-NPs are employed as the ultimate carrier for the delivery of therapeutically vital compounds. Ample variety of available CDs makes it suitable carrier or transporter to accommodate compounds of diverse nature for biomedical and pharmaceutical applications. The ability of CDs offering modification functional groups on its surface to allow encompassing of versatile molecules mainly by host guest interactions and electrostatic interactions. CDs has emerged it as appropriate candidate for theranostics applications due to its flexibility offering chemical modification which can act as (a) a core for development of highly branched star polymer (b) a bridge or linker for different polymer block (c) a gatekeeper for the inorganic NPs. CDs are graced with biocompatible characteristics and catalytic attributes for well-located, feasible, stimuli responsive smart delivery of molecules. ¹⁴⁸ Representative case studies of theranostic applications of CD are specified in Table 4. ^149-163

Conclusion and Future Perspective

The accumulated pieces evidence in last two decades conclusively demonstrates that CD can play versatile role in the improvement of nanoparticulate or nanovesicular drug delivery. The CD functionalization could be valuable for increasing drug loading, improving solubility, stability, permeability, absorption, bioavailability and modifying drug release with retaining safety and efficacy. Recently reported acetylated α-CD materials were used for pH-modulated hydrolysis and pH-triggered drug delivery of paclitaxel exploring the new generation of nanocarriers. ¹⁶⁴ Further chemical modifications of CDs and formulation studies are needed to exploit their applications in site specific controlled delivery of drugs through NPs which can be seen from the typical examples indicated in Table 5. ^165-173

The CD allows NPs to be tuned for tailor-made needs of drug delivery and theranostics through the chemical modifications demonstrating the scope for the researchers from the chemical, biomedical and pharmaceutical field to focus on the utilization of CD in nanoparticulate drug delivery.

Along with the issues discussed under this review it attracts our attention to the recent reports indicating the intervention of CD derivatives in the treatment of various diseases. CRLX 101 a β-CD based NP formulation has reported intervention for the treatment of various types of carcinoma including non small cell lung cancer, ovarian cancer, gastroesophageal cancer, etc. ¹⁷⁴ The reports showing safety of α-CD along with modest reduction in small low density lipoproteins, and an improvement in glucose related parameters and use of HP-β-CD for treatment of Niemann-Pick disease, type C1 provide as opportunity for synergistic delivery of the molecules used in the treatment of these diseases. ^175,176 Additionally, HP-β-CD is known to reduce local irritation antiviral intravenous formulation of letermovir. ¹⁷⁷ These studies unlock new avenues in the research of drug delivery science for better management opportunities of diseases and their side effects.

Ethical Issues

Not applicable.

Conflict of Interest

Authors declare no conflict of interest in this study.

Acknowledgments

The authors are grateful Dr. J.N. Sangshetti, Mr. Vishal A. Chakkarwar and Mr. Sachin R. Patil for their suggestions and revision of manuscript.

References

1. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009; 86(3):215-23. doi: 10.1016/j.yexmp.2008.12.004 [Crossref]
2. Fattal E. Drug Delivery: Nanoparticles. In: Swarbrick J, ed. Encyclopedia of Pharmaceutical Technology. Vol.2. New York: Informa Healthcare; 2007. p. 1183.
3. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Kiafar F, Jelvehgari M. Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Res Pharm Sci 2017; 12(1):1-14. doi: 10.4103/1735-5362.199041 [Crossref]
4. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8(24):1112-20. doi: 10.1016/s1359-6446(03)02903-9 [Crossref]
5. Jătariu AN, Popa M, Peptu CA. Different particulate systems--bypass the biological barriers?. J Drug Target 2010; 18(4):243-53. doi: 10.3109/10611860903398099 [Crossref]
6. Gupta RB, Kompella UB. Nanoparticle Technology for Drug Delivery. New York: Taylor & Francis; 2006.
7. Wackerlig J, Schirhagl R. Applications of molecularly imprinted polymer nanoparticles and their advances toward industrial use: a review. Anal Chem 2016; 88(1):250-61. doi: 10.1021/acs.analchem.5b03804 [Crossref]
8. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C 2016; 60:569-78. doi: 10.1016/j.msec.2015.11.067 [Crossref]
9. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2):170-84. doi: 10.1016/j.ijpharm.2008.10.003 [Crossref]
10. Zhou J, Zha X, Chen X, Ma J. β-Cyclodextrin-g-Poly (2-(dimethylamino) ethyl methacrylate) as the Stabilizer and Reductant to Prepare Colloid Silver Nanoparticles in situ. Indian J Pharm Educ Res 2017; 51(4):543-50. doi: 10.5530/ijper.51.4.83 [Crossref]
11. Namdari P, Negahdari B, Eatemadi A. Synthesis, properties and biomedical applications of carbon-based quantum dots: an updated review. Biomed Pharmacother 2017; 87:209-22. doi: 10.1016/j.biopha.2016.12.108 [Crossref]
12. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012; 8(2):147-66. doi: 10.1016/j.nano.2011.05.016 [Crossref]
13. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46(12 Pt 1):6387-92.
14. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 2015; 21(4):223-32. doi: 10.1016/j.molmed.2015.01.001 [Crossref]
15. Wong CY, Al-Salami H, Dass CR. The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. J Drug Target 2018; 26(7):551-62. doi: 10.1080/1061186x.2017.1400552 [Crossref]
16. Feng Y, He H, Li F, Lu Y, Qi J, Wu W. An update on the role of nanovehicles in nose-to-brain drug delivery. Drug Discov Today 2018; 23(5):1079-88. doi: 10.1016/j.drudis.2018.01.005 [Crossref]
17. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009; 71(2):161-72. doi: 10.1016/j.ejpb.2008.09.003 [Crossref]
18. Grimaudo MA, Nicoli S, Santi P, Concheiro A, Alvarez-Lorenzo C. Cyclosporine-loaded cross-linked inserts of sodium hyaluronan and hydroxypropyl-beta-cyclodextrin for ocular administration. Carbohydr Polym 2018; 201:308-16. doi: 10.1016/j.carbpol.2018.08.073 [Crossref]
19. Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H. Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. Int J Mol Sci 2019; 20(2). doi: 10.3390/ijms20020381 [Crossref]
20. Abdel-Hafez SM, Hathout RM, Sammour OA. Tracking the transdermal penetration pathways of optimized curcumin-loaded chitosan nanoparticles via confocal laser scanning microscopy. Int J Biol Macromol 2018; 108:753-64. doi: 10.1016/j.ijbiomac.2017.10.170 [Crossref]
21. Pathak Y, Thassu D, Deleers M. Nanoparticulate Drug Delivery Systems. New York: Informa Healthcare; 2007. p. 185-203.
22. Calleja P, Huarte J, Agüeros M, Ruiz-Gatón L, Espuelas S, Irache JM. Molecular buckets: cyclodextrins for oral cancer therapy. Ther Deliv 2012; 3(1):43-57. doi: 10.4155/tde.11.140 [Crossref]
23. Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, Loftsson T. Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. Int J Pharm 2012; 428(1-2):152-63. doi: 10.1016/j.ijpharm.2012.02.038 [Crossref]
24. Zhang J, Ma PX. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev 2013; 65(9):1215-33. doi: 10.1016/j.addr.2013.05.001 [Crossref]
25. Kanwar JR, Long BM, Kanwar RK. The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 2011; 18(14):2079-85. doi: 10.2174/092986711795656243 [Crossref]
26. Li JJ, Zhao F, Li J. Supramolecular polymers based on cyclodextrins for drug and gene delivery. Adv Biochem Eng Biotechnol 2011; 125:207-49. doi: 10.1007/10_2010_91 [Crossref]
27. Ortiz Mellet C, García Fernández JM, Benito JM. Cyclodextrin-based gene delivery systems. Chem Soc Rev 2011; 40(3):1586-608. doi: 10.1039/c0cs00019a [Crossref]
28. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2013; 453(1):167-80. doi: 10.1016/j.ijpharm.2012.06.055 [Crossref]
29. Vikas Y, Sandeep K, Braham D, Manjusha C, Budhwar V. Cyclodextrin Complexes: An Approach to Improve the Physicochemical Properties of Drugs and Applications of Cyclodextrin Complexes. Asian J Pharm 2018; 12(2):S394-S409. doi: 10.22377/ajp.v12i02.2367 [Crossref]
30. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329(1-2):1-11. doi: 10.1016/j.ijpharm.2006.10.044 [Crossref]
31. Hashimoto H. Present status of industrial application of cyclodextrins in Japan. J Incl Phenom Macrocycl Chem 2002; 44(1):57-62. doi: 10.1023/A:1023036406829 [Crossref]
32. Liu Y, Li J. Advances of cyclodextrin polymers for the delivery of biotech drugs. J Bioresour Bioprod 2016; 1(1):7-17. doi: 10.21967/jbb.v1i1.38 [Crossref]
33. Rogers MA. Naturally occurring nanoparticles in food. Curr Opin Food Sci 2016; 7:14-9. doi: 10.1016/j.cofs.2015.08.005 [Crossref]
34. Fourmentin S, Crini G, Lichtfouse E. Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals. Springer; 2018.
35. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010; 62(11):1607-21. doi: 10.1111/j.2042-7158.2010.01030.x [Crossref]
36. Jambhekar SS, Breen P. Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today 2016; 21(2):356-62. doi: 10.1016/j.drudis.2015.11.017 [Crossref]
37. Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. J Drug Target 2010; 18(9):645-56. doi: 10.3109/10611861003622552 [Crossref]
38. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005; 6(2):E329-57. doi: 10.1208/pt060243 [Crossref]
39. Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005; 2(2):335-51. doi: 10.1517/17425247.2.1.335 [Crossref]
40. Menezes PDP, Andrade TA, Frank LA, de Souza E, Trindade G, Trindade IAS. Advances of nanosystems containing cyclodextrins and their applications in pharmaceuticals. Int J Pharm 2019; 559:312-28. doi: 10.1016/j.ijpharm.2019.01.041 [Crossref]
41. O’Neill MJ, Guo J, Byrne C, Darcy R, O’Driscoll CM. Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells. Int J Pharm 2011; 413(1-2):174-83. doi: 10.1016/j.ijpharm.2011.04.021 [Crossref]
42. Sharma N, Baldi A. Exploring versatile applications of cyclodextrins: an overview. Drug Deliv 2016; 23(3):739-57. doi: 10.3109/10717544.2014.938839 [Crossref]
43. Zhang J, Ellsworth K, Ma PX. Hydrophobic pharmaceuticals mediated self-assembly of beta-cyclodextrin containing hydrophilic copolymers: novel chemical responsive nano-vehicles for drug delivery. J Control Release 2010; 145(2):116-23. doi: 10.1016/j.jconrel.2010.04.019 [Crossref]
44. Eguchi M, Du YZ, Ogawa Y, Okada T, Yumoto N, Kodaka M. Effects of conditions for preparing nanoparticles composed of aminoethylcarbamoyl-beta-cyclodextrin and ethylene glycol diglycidyl ether on trap efficiency of a guest molecule. Int J Pharm 2006; 311(1-2):215-22. doi: 10.1016/j.ijpharm.2005.12.015 [Crossref]
45. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 2007; 18(2):456-68. doi: 10.1021/bc0603539 [Crossref]
46. Baek JS, Kim BS, Puri A, Kumar K, Cho CW. Stability of paclitaxel-loaded solid lipid nanoparticles in the presence of 2-hydoxypropyl-beta-cyclodextrin. Arch Pharm Res 2016; 39(6):785-93. doi: 10.1007/s12272-016-0753-5 [Crossref]
47. Gèze A, Aous S, Baussanne I, Putaux J, Defaye J, Wouessidjewe D. Influence of chemical structure of amphiphilic beta-cyclodextrins on their ability to form stable nanoparticles. Int J Pharm 2002; 242(1-2):301-5. doi: 10.1016/s0378-5173(02)00192-8 [Crossref]
48. Samra HS, He F, Bhambhani A, Pipkin JD, Zimmerer R, Joshi SB. The effects of substituted cyclodextrins on the colloidal and conformational stability of selected proteins. J Pharm Sci 2010; 99(6):2800-18. doi: 10.1002/jps.22053 [Crossref]
49. Mooguee M, Omidi Y, Davaran S. Synthesis and in vitro release of adriamycin from star-shaped poly(lactide-co-glycolide) nano- and microparticles. J Pharm Sci 2010; 99(8):3389-97. doi: 10.1002/jps.22106 [Crossref]
50. Lemos-Senna E, Wouessidjewe D, Lesieur S, Puisieux F, Couarraze G, Duchěne D. Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres. Pharm Dev Technol 1998; 3(1):85-94. doi: 10.3109/10837459809028482 [Crossref]
51. Eguchi M, Du YZ, Taira S, Kodaka M. Functional nanoparticle based on beta-cyclodextrin: preparation and properties. Nanobiotechnology 2005; 1(2):165-9. doi: 10.1385/nbt:1:2:165 [Crossref]
52. Memisoglu-Bilensoy E, Sen M, Hincal AA. Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules. J Microencapsul 2006; 23(1):59-68. doi: 10.1080/02652040500286227 [Crossref]
53. Charman SA, Perry CS, Chiu FC, McIntosh KA, Prankerd RJ, Charman WN. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci 2006; 95(2):256-67. doi: 10.1002/jps.20534 [Crossref]
54. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins 1 Drug solubilization and stabilization. J Pharm Sci 1996; 85(10):1017-25. doi: 10.1021/js950534b [Crossref]
55. Stancanelli R, Guardo M, Cannavà C, Guglielmo G, Ficarra P, Villari V. Amphiphilic cyclodextrins as nanocarriers of genistein: a spectroscopic investigation pointing out the structural properties of the host/drug complex system. J Pharm Sci 2010; 99(7):3141-9. doi: 10.1002/jps.22065 [Crossref]
56. Qiu N, Cai L, Wang W, Wang G, Cheng X, Xu Q. Barbigerone-in-hydroxypropyl-beta-cyclodextrin-liposomal nanoparticle: preparation, characterization and anti-cancer activities. J Incl Phenom Macrocycl Chem 2015; 82(3):505-14. doi: 10.1007/s10847-015-0533-8 [Crossref]
57. Duchene D, Cavalli R, Gref R. Cyclodextrin-based polymeric nanoparticles as efficient carriers for anticancer drugs. Curr Pharm Biotechnol 2016; 17(3):248-55. doi: 10.2174/1389201017666151030104944 [Crossref]
58. Miyazaki Y, Sugihara H, Nishiura A, Kadota K, Tozuka Y, Takeuchi H. Appropriate selection of an aggregation inhibitor of fine particles used for inhalation prepared by emulsion solvent diffusion. Drug Dev Ind Pharm 2017; 43(1):30-41. doi: 10.1080/03639045.2016.1201099 [Crossref]
59. Pant A, Negi JS. Novel controlled ionic gelation strategy for chitosan nanoparticles preparation using TPP-beta-CD inclusion complex. Eur J Pharm Sci 2018; 112:180-5. doi: 10.1016/j.ejps.2017.11.020 [Crossref]
60. Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009; 38(4):405-13. doi: 10.1016/j.ejps.2009.09.010 [Crossref]
61. Yuan Z, Ye Y, Gao F, Yuan H, Lan M, Lou K. Chitosan-graft-beta-cyclodextrin nanoparticles as a carrier for controlled drug release. Int J Pharm 2013; 446(1-2):191-8. doi: 10.1016/j.ijpharm.2013.02.024 [Crossref]
62. Memişoğlu E, Bochot A, Ozalp M, Sen M, Duchêne D, Hincal AA. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res 2003; 20(1):117-25. doi: 10.1023/a:1022263111961 [Crossref]
63. Trapani A, Sitterberg J, Bakowsky U, Kissel T. The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int J Pharm 2009; 375(1-2):97-106. doi: 10.1016/j.ijpharm.2009.03.041 [Crossref]
64. Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol 2019; 122:338-47. doi: 10.1016/j.ijbiomac.2018.10.181 [Crossref]
65. Abdelwahed W, Degobert G, Dubes A, Parrot-Lopez H, Fessi H. Sulfated and non-sulfated amphiphilic-beta-cyclodextrins: impact of their structural properties on the physicochemical properties of nanoparticles. Int J Pharm 2008; 351(1-2):289-95. doi: 10.1016/j.ijpharm.2007.09.035 [Crossref]
66. Chen XM, Chen Y, Hou XF, Wu X, Gu BH, Liu Y. Sulfonato-beta-cyclodextrin mediated supramolecular nanoparticle for controlled release of berberine. ACS Appl Mater Interfaces 2018; 10(30):24987-92. doi: 10.1021/acsami.8b08651 [Crossref]
67. Mandava K, Kadimcharla K, Keesara NR, Fatima SN, Bommena P, Batchu UR. Green synthesis of stable copper nanoparticles and synergistic activity with antibiotics. Indian J Pharm Sci 2017; 79(5):695-700. doi: 10.4172/pharmaceutical-sciences.1000281 [Crossref]
68. Baek JS, Cho CW. 2-Hydroxypropyl-beta-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J Pharm Pharmacol 2013; 65(1):72-8. doi: 10.1111/j.2042-7158.2012.01578.x [Crossref]
69. Wang Z, Li Y. Raloxifene/SBE-beta-CD inclusion complexes formulated into nanoparticles with chitosan to overcome the absorption barrier for bioavailability enhancement. Pharmaceutics 2018; 10(3). doi: 10.3390/pharmaceutics10030076 [Crossref]
70. Cirpanli Y, Bilensoy E, Lale Doğan A, Caliş S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm 2009; 73(1):82-9. doi: 10.1016/j.ejpb.2009.04.013 [Crossref]
71. Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym 2016; 137:339-49. doi: 10.1016/j.carbpol.2015.10.080 [Crossref]
72. Kim MS. Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-beta-cyclodextrin nanostructures. Int J Nanomedicine 2013; 8:2029-39. doi: 10.2147/ijn.s44795 [Crossref]
73. Huarte J, Espuelas S, Lai Y, He B, Tang J, Irache JM. Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles. Int J Pharm 2016; 506(1-2):116-28. doi: 10.1016/j.ijpharm.2016.04.045 [Crossref]
74. Rachmawati H, Edityaningrum CA, Mauludin R. Molecular inclusion complex of curcumin-beta-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel. AAPS PharmSciTech 2013; 14(4):1303-12. doi: 10.1208/s12249-013-0023-5 [Crossref]
75. Song M, Wang H, Chen K, Zhang S, Yu L, Elshazly EH. Oral insulin delivery by carboxymethyl-beta-cyclodextrin-grafted chitosan nanoparticles for improving diabetic treatment. Artif Cells Nanomed Biotechnol 2018; 46(sup3):S774-s82. doi: 10.1080/21691401.2018.1511575 [Crossref]
76. Mansourpour M, Mahjub R, Amini M, Ostad SN, Shamsa ES, Rafiee-Tehrani M. Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic beta-cyclodextrin polymers for insulin oral delivery. AAPS PharmSciTech 2015; 16(4):952-62. doi: 10.1208/s12249-014-0282-9 [Crossref]
77. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006; 325(1-2):147-54. doi: 10.1016/j.ijpharm.2006.06.019 [Crossref]
78. Song M, Li L, Zhang Y, Chen K, Wang H, Gong R. Carboxymethyl-β-cyclodextrin grafted chitosan nanoparticles as oral delivery carrier of protein drugs. React Funct Polym 2017; 117:10-5. doi: 10.1016/j.reactfunctpolym.2017.05.008 [Crossref]
79. Nafee N, Hirosue M, Loretz B, Wenz G, Lehr CM. Cyclodextrin-based star polymers as a versatile platform for nanochemotherapeutics: enhanced entrapment and uptake of idarubicin. Colloids Surf B Biointerfaces 2015; 129:30-8. doi: 10.1016/j.colsurfb.2015.03.014 [Crossref]
80. Loftsson T, Vogensen SB, Brewster ME, Konrádsdóttir F. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 2007; 96(10):2532-46. doi: 10.1002/jps.20992 [Crossref]
81. Wu J, Shen Q, Fang L. Sulfobutylether-beta-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Drug Dev Ind Pharm 2013; 39(7):1010-9. doi: 10.3109/03639045.2012.694588 [Crossref]
82. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010; 6(1):9-24. doi: 10.1016/j.nano.2009.04.008 [Crossref]
83. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009; 6(3):659-68. doi: 10.1021/mp900015y [Crossref]
84. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464(7291):1067-70. doi: 10.1038/nature08956 [Crossref]
85. Quan CY, Chen JX, Wang HY, Li C, Chang C, Zhang XZ. Core-shell nanosized assemblies mediated by the alpha-beta cyclodextrin dimer with a tumor-triggered targeting property. ACS Nano 2010; 4(7):4211-9. doi: 10.1021/nn100534q [Crossref]
86. Zhu Y, Che L, He H, Jia Y, Zhang J, Li X. Highly efficient nanomedicines assembled via polymer-drug multiple interactions: Tissue-selective delivery carriers. J Control Release 2011; 152(2):317-24. doi: 10.1016/j.jconrel.2011.03.013 [Crossref]
87. Dai Y, Zhang X. Dual stimuli-responsive supramolecular polymeric nanoparticles based on poly(alpha-cyclodextrin) and acetal-modified beta -cyclodextrin-azobenzene. J Polym Res 2018; 25(4):102. doi: 10.1007/s10965-018-1503-9 [Crossref]
88. Malhotra M, Gooding M, Evans JC, O’Driscoll D, Darcy R, O’Driscoll CM. Cyclodextrin-siRNA conjugates as versatile gene silencing agents. Eur J Pharm Sci 2018; 114:30-7. doi: 10.1016/j.ejps.2017.11.024 [Crossref]
89. Alizadeh D, Zhang L, Hwang J, Schluep T, Badie B. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine 2010; 6(2):382-90. doi: 10.1016/j.nano.2009.10.001 [Crossref]
90. Wang A, Jin W, Chen E, Zhou J, Zhou L, Wei S. Drug delivery function of carboxymethyl-beta-cyclodextrin modified upconversion nanoparticles for adamantine phthalocyanine and their NIR-triggered cancer treatment. Dalton Trans 2016; 45(9):3853-62. doi: 10.1039/c5dt04900h [Crossref]
91. Ben Zirar S, Astier A, Muchow M, Gibaud S. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 2008; 70(2):649-56. doi: 10.1016/j.ejpb.2008.05.012 [Crossref]
92. Chen Y, Li N, Yang Y, Liu Y. A dual targeting cyclodextrin/gold nanoparticle conjugate as a scaffold for solubilization and delivery of paclitaxel. RSC Adv 2015; 5(12):8938-41. doi: 10.1039/c4ra13135e [Crossref]
93. Popat A, Karmakar S, Jambhrunkar S, Xu C, Yu C. Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity. Colloids Surf B Biointerfaces 2014; 117:520-7. doi: 10.1016/j.colsurfb.2014.03.005 [Crossref]
94. Hattori K. Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent. European Patent EP 2194068B1, April 17, 2013.
95. Erdoğar N, Varan G, Varan C, Bilensoy E. Cyclodextrin-based polymeric nanosystems. In: Grumezescu AM, ed. Drug Targeting and Stimuli Sensitive Drug Delivery Systems. William Andrew Publishing; 2018. p. 715-48. 10.1016/B978-0-12-813689-8.00019-7
96. Lakkakula JR, Maçedo Krause RW. A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Nanomedicine (Lond) 2014; 9(6):877-94. doi: 10.2217/nnm.14.41 [Crossref]
97. Ahmed A, Yadav HK, Lakshmi SV, Namburi BV, Shivakumar HG. Mucoadhesive nanoparticulate system for oral drug delivery: a review. Curr Drug ther 2012; 7(1):42-55. doi: 10.2174/157488512800389137 [Crossref]
98. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. Chitosan/sulfobutylether-beta-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011; 413(1-2):229-36. doi: 10.1016/j.ijpharm.2011.04.031 [Crossref]
99. Liu Y, Zhai Y, Han X, Liu X, Liu W, Wu C. Bioadhesive chitosan-coated cyclodextrin-based superamolecular nanomicelles to enhance the oral bioavailability of doxorubicin. J Nanopart Res 2014; 16(10):2587. doi: 10.1007/s11051-014-2587-8 [Crossref]
100. Ojer P, Neutsch L, Gabor F, Irache JM, López de Cerain A. Cytotoxicity and cell interaction studies of bioadhesive poly(anhydride) nanoparticles for oral antigen/drug delivery. J Biomed Nanotechnol 2013; 9(11):1891-903. doi: 10.1166/jbn.2013.1695 [Crossref]
101. Zhang Q, Neoh KG, Xu L, Lu S, Kang ET, Mahendran R. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir 2014; 30(21):6151-61. doi: 10.1021/la500746e [Crossref]
102. Jeganath S, Asha D, Kumar SS, Nair KS, Senthilkumaran K. Oral controlled drug delivery system – a review. Res J Pharm Technol 2018; 11(2):797-804. doi: 10.5958/0974-360X.2018.00151.8 [Crossref]
103. Gonzalez-Gaitano G, Isasi JR, Velaz I, Zornoza A. Drug carrier systems based on cyclodextrin supramolecular assemblies and polymers: present and perspectives. Curr Pharm Des 2017; 23(3):411-32. doi: 10.2174/1381612823666161118145309 [Crossref]
104. Hu QD, Tang GP, Chu PK. Cyclodextrin-based host-guest supramolecular nanoparticles for delivery: from design to applications. Acc Chem Res 2014; 47(7):2017-25. doi: 10.1021/ar500055s [Crossref]
105. Lakkakula JR, Matshaya T, Krause RW. Cationic cyclodextrin/alginate chitosan nanoflowers as 5-fluorouracil drug delivery system. Mater Sci Eng C Mater Biol Appl 2017; 70(Pt 1):169-77. doi: 10.1016/j.msec.2016.08.073 [Crossref]
106. de Azevedo Mde B, Tasic L, Fattori J, Rodrigues FH, Cantos FC, Ribeiro LP. New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles. Int J Nanomedicine 2011; 6:1005-16. doi: 10.2147/ijn.s18999 [Crossref]
107. Gallego-Yerga L, Posadas I, de la Torre C, Ruiz-Almansa J, Sansone F, Ortiz Mellet C. Docetaxel-loaded nanoparticles assembled from beta-cyclodextrin/calixarene giant surfactants: physicochemical properties and cytotoxic effect in prostate cancer and glioblastoma cells. Front Pharmacol 2017; 8:249. doi: 10.3389/fphar.2017.00249 [Crossref]
108. Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 2009; 61(13):1189-92. doi: 10.1016/j.addr.2009.05.005 [Crossref]
109. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 2009; 30(3):374-82. doi: 10.1016/j.biomaterials.2008.09.035 [Crossref]
110. Gao H, Wang YN, Fan YG, Ma JB. Conjugates of poly (DL-lactide-co-glycolide) on amino cyclodextrins and their nanoparticles as protein delivery system. J Biomed Mater Res A 2007; 80(1):111-22. doi: 10.1002/jbm.a.30861 [Crossref]
111. Yin L, Xu S, Feng Z, Deng H, Zhang J, Gao H. Supramolecular hydrogel based on high-solid-content mPECT nanoparticles and cyclodextrins for local and sustained drug delivery. Biomater Sci 2017; 5(4):698-706. doi: 10.1039/c6bm00889e [Crossref]
112. Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005; 43(10):1451-9. doi: 10.1016/j.fct.2005.03.007 [Crossref]
113. Healing G, Sulemann T, Cotton P, Harris J, Hargreaves A, Finney R. Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ss-cyclodextrin causes renal toxicity. J Appl Toxicol 2016; 36(1):140-50. doi: 10.1002/jat.3155 [Crossref]
114. Shende P, Kulkarni YA, Gaud RS, Deshmukh K, Cavalli R, Trotta F. Acute and repeated dose toxicity studies of different beta-cyclodextrin-based nanosponge formulations. J Pharm Sci 2015; 104(5):1856-63. doi: 10.1002/jps.24416 [Crossref]
115. Gritli I, Garmey E, Eliasof S, Tellez A, Davis ME, Yun Y. Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101. In: Braddock M, ed. Nanomedicines: Design, Delivery and Detection. Cambridge, UK: Royal Society of Chemistry; 2016. p. 199-232. 10.1039/9781782622536-00199
116. Liu G, Wang R, Yan Y, Fan L, Xue J, Wang T. The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: a systematic review. Sci Rep 2017; 7(1):5724. doi: 10.1038/s41598-017-06159-2 [Crossref]
117. Gidwani B, Vyas A. A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. Biomed Res Int 2015; 2015:198268. doi: 10.1155/2015/198268 [Crossref]
118. Kim TK, Yoo HH. Anticancer effect of docetaxel/hydroxypropyl-beta-cyclodextrin complex without histamine release. J Incl Phenom Macrocycl Chem 2015; 83(3-4):355-61. doi: 10.1007/s10847-015-0571-2 [Crossref]
119. Hwang J, Rodgers K, Oliver JC, Schluep T. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomedicine 2008; 3(3):359-71. doi: 10.2147/ijn.s3217 [Crossref]
120. Memisoglu-Bilensoy E, Doǧan AL, Hincal AA. Cytotoxic evaluation of injectable cyclodextrin nanoparticles. J Pharm Pharmacol 2006; 58(5):585-9. doi: 10.1211/jpp.58.5.0002 [Crossref]
121. Cavalli R, Donalisio M, Bisazza A, Civra A, Ranucci E, Ferruti P. Enhanced antiviral activity of acyclovir loaded into nanoparticles. Methods Enzymol 2012; 509:1-19. doi: 10.1016/b978-0-12-391858-1.00001-0 [Crossref]
122. Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotechnol 2013; 9(6):998-1007. doi: 10.1166/jbn.2013.1594 [Crossref]
123. Varan G, Varan C, Erdoğar N, Hincal AA, Bilensoy E. Amphiphilic cyclodextrin nanoparticles. Int J Pharm 2017; 531(2):457-69. doi: 10.1016/j.ijpharm.2017.06.010 [Crossref]
124. Yang W, Chow KT, Lang B, Wiederhold NP, Johnston KP, Williams RO, 3rd 3rd. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. Eur J Pharm Sci 2010; 39(5):336-47. doi: 10.1016/j.ejps.2010.01.001 [Crossref]
125. Salzano G, Wankar J, Ottani S, Villemagne B, Baulard AR, Willand N. Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs. Int J Pharm 2017; 531(2):577-87. doi: 10.1016/j.ijpharm.2017.05.030 [Crossref]
126. Vartiainen V, Bimbo LM, Hirvonen J, Kauppinen EI, Raula J. Aerosolization, drug permeation and cellular interaction of dry powder pulmonary formulations of corticosteroids with hydroxypropyl-beta-cyclodextrin as a solubilizer. Pharm Res 2017; 34(1):25-35. doi: 10.1007/s11095-016-2035-9 [Crossref]
127. Machelart A, Salzano G, Li X, Demars A, Debrie AS, Menendez-Miranda M. Intrinsic Antibacterial Activity of Nanoparticles Made of beta-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. ACS Nano 2019; 13(4):3992-4007. doi: 10.1021/acsnano.8b07902 [Crossref]
128. Hong S, Li Z, Li C, Dong C, Shuang S. beta-Cyclodextrin grafted polypyrrole magnetic nanocomposites toward the targeted delivery and controlled release of doxorubicin. Appl Surf Sci 2018; 427:1189-98. doi: 10.1016/j.apsusc.2017.08.201 [Crossref]
129. Zhang P, Liu X, Hu W, Bai Y, Zhang L. Preparation and evaluation of naringenin-loaded sulfobutylether-beta-cyclodextrin/chitosan nanoparticles for ocular drug delivery. Carbohydr Polym 2016; 149:224-30. doi: 10.1016/j.carbpol.2016.04.115 [Crossref]
130. Jóhannsdóttir S, Kristinsson JK, Fülöp Z, Ásgrímsdóttir G, Stefánsson E, Loftsson T. Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles. Int J Pharm 2017; 529(1-2):486-90. doi: 10.1016/j.ijpharm.2017.07.044 [Crossref]
131. Xiang S, Tang HW, Zhou J, Li XZ. Electrospinning of Hydroxypropyl-beta-cyclodextrin/Polyvinylpyrrolidone Resveratrol-loaded Nanofibers: Preparation and Characterization. Indian J Pharm Sci 2019; 81(4):618-25. doi: 10.36468/pharmaceutical-sciences.552 [Crossref]
132. Lucio D, Martínez-Ohárriz MC, Gu Z, He Y, Aranaz P, Vizmanos JL. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration In vivo evaluation using C elegans. Int J Pharm 2018; 547(1-2):97-105. doi: 10.1016/j.ijpharm.2018.05.064 [Crossref]
133. Sakulwech S, Lourith N, Ruktanonchai U, Kanlayavattanakul M. Preparation and characterization of nanoparticles from quaternized cyclodextrin-grafted chitosan associated with hyaluronic acid for cosmetics. Asian J Pharm Sci 2018; 13(5):498-504. doi: 10.1016/j.ajps.2018.05.006 [Crossref]
134. Yakavets I, Lassalle HP, Scheglmann D, Wiehe A, Zorin V, Bezdetnaya L. Temoporfin-in-Cyclodextrin-in-Liposome-A New Approach for Anticancer Drug Delivery: The Optimization of Composition. Nanomaterials (Basel) 2018; 8(10). doi: 10.3390/nano8100847 [Crossref]
135. Belgamwar AV, Khan SA, Yeole PG. Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta-cyclodextrin for brain delivery in Neuro-AIDS. J Drug Deliv Sci Technol 2019; 52:1008-20. doi: 10.1016/j.jddst.2019.06.014 [Crossref]
136. Belgamwar A, Khan S, Yeole P. Intranasal chitosan-g-HPbetaCD nanoparticles of efavirenz for the CNS targeting. Artif Cells Nanomed Biotechnol 2018; 46(2):374-86. doi: 10.1080/21691401.2017.1313266 [Crossref]
137. Vinuesa T, Herraez R, Oliver L, Elizondo E, Acarregui A, Esquisabel A. Benznidazole Nanoformulates: a chance to improve therapeutics for Chagas disease. Am J Trop Med Hyg 2017; 97(5):1469-76. doi: 10.4269/ajtmh.17-0044 [Crossref]
138. Gholibegloo E, Mortezazadeh T, Salehian F, Ramazani A, Amanlou M, Khoobi M. Improved curcumin loading, release, solubility and toxicity by tuning the molar ratio of cross-linker to beta-cyclodextrin. Carbohydr Polym 2019; 213:70-8. doi: 10.1016/j.carbpol.2019.02.075 [Crossref]
139. Jiang Y, Pan X, Chang J, Niu W, Hou W, Kuai H. Supramolecularly engineered circular bivalent aptamer for enhanced functional protein delivery. J Am Chem Soc 2018; 140(22):6780-4. doi: 10.1021/jacs.8b03442 [Crossref]
140. Shen Y, Li M, Liu T, Liu J, Xie Y, Zhang J. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. Int J Nanomedicine 2019; 14:4029-44. doi: 10.2147/ijn.s201688 [Crossref]
141. Shelley H, Babu RJ. Role of cyclodextrins in nanoparticle-based drug delivery systems. J Pharm Sci 2018; 107(7):1741-53. doi: 10.1016/j.xphs.2018.03.021 [Crossref]
142. Mejia-Ariza R, Graña-Suárez L, Verboom W, Huskens J. Cyclodextrin-based supramolecular nanoparticles for biomedical applications. J Mater Chem B 2017; 5(1):36-52. doi: 10.1039/c6tb02776h [Crossref]
143. Adeoye O, Cabral-Marques H. Cyclodextrin nanosystems in oral drug delivery: a mini review. Int J Pharm 2017; 531(2):521-31. doi: 10.1016/j.ijpharm.2017.04.050 [Crossref]
144. Bonnet V, Gervaise C, Djedaïni-Pilard F, Furlan A, Sarazin C. Cyclodextrin nanoassemblies: a promising tool for drug delivery. Drug Discov Today 2015; 20(9):1120-6. doi: 10.1016/j.drudis.2015.05.008 [Crossref]
145. Muankaew C, Loftsson T. Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery. Basic Clin Pharmacol Toxicol 2018; 122(1):46-55. doi: 10.1111/bcpt.12917 [Crossref]
146. Jo SD, Ku SH, Won YY, Kim SH, Kwon IC. Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy. Theranostics 2016; 6(9):1362-77. doi: 10.7150/thno.15335 [Crossref]
147. Li L, Wang J, Kong H, Zeng Y, Liu G. Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment. Sci Technol Adv Mater 2018; 19(1):771-90. doi: 10.1080/14686996.2018.1528850 [Crossref]
148. Yao X, Mu J, Zeng L, Lin J, Nie Z, Jiang X. Stimuli-responsive cyclodextrin-based nanoplatforms for cancer treatment and theranostics. Mater Horiz 2019; 6(5):846-70. doi: 10.1039/c9mh00166b [Crossref]
149. Mortezazadeh T, Gholibegloo E, Alam NR, Dehghani S, Haghgoo S, Ghanaati H. Gadolinium (III) oxide nanoparticles coated with folic acid-functionalized poly (beta-cyclodextrin-co-pentetic acid) as a biocompatible targeted nano-contrast agent for cancer diagnostic: in vitro and in vivo studies. MAGMA 2019; 32(4):487-500. doi: 10.1007/s10334-019-00738-2 [Crossref]
150. Oroujeni M, Kaboudin B, Xia W, Jönsson P, Ossipov DA. Conjugation of cyclodextrin to magnetic Fe3O4 nanoparticles via polydopamine coating for drug delivery. Prog Org Coat 2018; 114:154-61. doi: 10.1016/j.porgcoat.2017.10.007 [Crossref]
151. Piras AM, Fabiano A, Chiellini F, Zambito Y. Methyl-beta-cyclodextrin quaternary ammonium chitosan conjugate: nanoparticles vs macromolecular soluble complex. Int J Nanomedicine 2018; 13:2531-41. doi: 10.2147/ijn.s160987 [Crossref]
152. Barlas FB, Aydindogan E, Arslan M, Timur S, Yagci Y. Gold nanoparticle conjugated poly (p-phenylene-beta-cyclodextrin)-graft-poly (ethylene glycol) for theranostic applications. J Appl Polym Sci 2019; 136(12):47250. doi: 10.1002/app.47250 [Crossref]
153. Das M, Solanki A, Joshi A, Devkar R, Seshadri S, Thakore S. beta-cyclodextrin based dual-responsive multifunctional nanotheranostics for cancer cell targeting and dual drug delivery. Carbohydr Polym 2019; 206:694-705. doi: 10.1016/j.carbpol.2018.11.049 [Crossref]
154. Yang GG, Zhang H, Zhang DY, Cao Q, Yang J, Ji LN. Cancer-specific chemotherapeutic strategy based on the vitamin K3 mediated ROS regenerative feedback and visualized drug release in vivo. Biomaterials 2018; 185:73-85. doi: 10.1016/j.biomaterials.2018.08.065 [Crossref]
155. Song S, Chong Y, Fu H, Ning X, Shen H, Zhang Z. HP-beta-CD Functionalized Fe3O4/CNPs-Based Theranostic Nanoplatform for pH/NIR Responsive Drug Release and MR/NIRFL Imaging-Guided Synergetic Chemo/Photothermal Therapy of Tumor. ACS Appl Mater Interfaces 2018; 10(40):33867-78. doi: 10.1021/acsami.8b09999 [Crossref]
156. Datz S, Illes B, Gossl D, Schirnding CV, Engelke H, Bein T. Biocompatible crosslinked beta-cyclodextrin nanoparticles as multifunctional carriers for cellular delivery. Nanoscale 2018; 10(34):16284-92. doi: 10.1039/c8nr02462f [Crossref]
157. Cha R, Li J, Liu Y, Zhang Y, Xie Q, Zhang M. Fe3O4 nanoparticles modified by CD-containing star polymer for MRI and drug delivery. Colloids Surf B Biointerfaces 2017; 158:213-21. doi: 10.1016/j.colsurfb.2017.06.049 [Crossref]
158. Lin W, Yao N, Qian L, Zhang X, Chen Q, Wang J. pH-responsive unimolecular micelle-gold nanoparticles-drug nanohybrid system for cancer theranostics. Acta Biomater 2017; 58:455-65. doi: 10.1016/j.actbio.2017.06.003 [Crossref]
159. Badruddoza AZ, Rahman MT, Ghosh S, Hossain MZ, Shi J, Hidajat K. beta-Cyclodextrin conjugated magnetic, fluorescent silica core-shell nanoparticles for biomedical applications. Carbohydr Polym 2013; 95(1):449-57. doi: 10.1016/j.carbpol.2013.02.046 [Crossref]
160. Shen J, Kim HC, Su H, Wang F, Wolfram J, Kirui D. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 2014; 4(5):487-97. doi: 10.7150/thno.8263 [Crossref]
161. Heo DN, Yang DH, Moon HJ, Lee JB, Bae MS, Lee SC. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 2012; 33(3):856-66. doi: 10.1016/j.biomaterials.2011.09.064 [Crossref]
162. Mrówczyński R, Jędrzak A, Szutkowski K, Grześkowiak BF, Coy E, Markiewicz R. Cyclodextrin-based magnetic nanoparticles for cancer therapy. Nanomaterials (Basel) 2018; 8(3). doi: 10.3390/nano8030170 [Crossref]
163. Ma X, Li X, Shi J, Yao M, Zhang X, Hou R. Host–Guest Polypyrrole Nanocomplex for Three-Stimuli-Responsive Drug Delivery and Imaging-Guided Chemo-Photothermal Synergetic Therapy of Refractory Thyroid Cancer. Adv Healthc Mater 2019; 8(17):1900661. doi: 10.1002/adhm.201900661 [Crossref]
164. He H, Chen S, Zhou J, Dou Y, Song L, Che L. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013; 34(21):5344-58. doi: 10.1016/j.biomaterials.2013.03.068 [Crossref]
165. Guo J, Ogier JR, Desgranges S, Darcy R, O’Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012; 33(31):7775-84. doi: 10.1016/j.biomaterials.2012.07.012 [Crossref]
166. Aykaç A, Martos-Maldonado MC, Casas-Solvas JM, Quesada-Soriano I, García-Maroto F, García-Fuentes L. beta-Cyclodextrin-bearing gold glyconanoparticles for the development of site specific drug delivery systems. Langmuir 2014; 30(1):234-42. doi: 10.1021/la403454p [Crossref]
167. Tarasi R, Khoobi M, Niknejad H, Ramazani A, Ma’mani L, Bahadorikhalili S. beta-cyclodextrin functionalized poly (5-amidoisophthalicacid) grafted Fe3O4 magnetic nanoparticles: a novel biocompatible nanocomposite for targeted docetaxel delivery. J Magn Magn Mater 2016; 417:451-9. doi: 10.1016/j.jmmm.2016.05.080 [Crossref]
168. Ye Y, Sun Y, Zhao H, Lan M, Gao F, Song C. A novel lactoferrin-modified beta-cyclodextrin nanocarrier for brain-targeting drug delivery. Int J Pharm 2013; 458(1):110-7. doi: 10.1016/j.ijpharm.2013.10.005 [Crossref]
169. Aranda C, Urbiola K, Méndez Ardoy A, García Fernández JM, Ortiz Mellet C, de Ilarduya CT. Targeted gene delivery by new folate-polycationic amphiphilic cyclodextrin-DNA nanocomplexes in vitro and in vivo. Eur J Pharm Biopharm 2013; 85(3 Pt A):390-7. doi: 10.1016/j.ejpb.2013.06.011 [Crossref]
170. Poudel AJ, He F, Huang L, Xiao L, Yang G. Supramolecular hydrogels based on poly (ethylene glycol)-poly (lactic acid) block copolymer micelles and alpha-cyclodextrin for potential injectable drug delivery system. Carbohydr Polym 2018; 194:69-79. doi: 10.1016/j.carbpol.2018.04.035 [Crossref]
171. Chen P, Song H, Yao S, Tu X, Su M, Zhou L. Magnetic targeted nanoparticles based on beta-cyclodextrin and chitosan for hydrophobic drug delivery and a study of their mechanism. RSC Adv 2017; 7(46):29025-34. doi: 10.1039/c7ra02398g [Crossref]
172. Lv Y, Hao L, Hu W, Ran Y, Bai Y, Zhang L. Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting. Sci Rep 2016; 6:29321. doi: 10.1038/srep29321 [Crossref]
173. Singh P, Ren X, He Y, Wu L, Wang C, Li H. Fabrication of beta-cyclodextrin and sialic acid copolymer by single pot reaction to site specific drug delivery. Arab J Chem 2020; 13(1):1397-405. doi: 10.1016/j.arabjc.2017.11.011 [Crossref]
174. U.S. National Library of Medicine- ClinicalTrials.gov 2019; Available from: https://clinicaltrials.gov/. Accessed August 29, 2019.
175. Farmer CA, Thurm A, Farhat N, Bianconi S, Keener LA, Porter FD. Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-beta-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1. CNS Drugs 2019; 33(7):677-83. doi: 10.1007/s40263-019-00642-2 [Crossref]
176. Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 2017; 390(10104):1758-68. doi: 10.1016/s0140-6736(17)31465-4 [Crossref]
177. Erb-Zohar K, Kropeit D, Scheuenpflug J, Stobernack HP, Hulskotte E, van Schanke A. Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase i, randomized, single-ascending, and multiple-dose trial. Clin Transl Sci 2017; 10(6):487-95. doi: 10.1111/cts.12483 [Crossref]